Activated regulatory and effector T cells imbalance in chronic HCV : Relation to autoimmunity / Ahmed Reda Sayed ; Supervised Hanan Hassan Fouad , Eman Medhat Hassan , Ghada Mahmoud Abdelaziz
Material type:
- الخلل فى الخلايا التائية التنظيميه المنشطه و المستجيبه فى مرضى فيروس سى الكبدى المزمن : و العلاقه بالمناعة الذاتية [Added title page title]
- Issued also as CD
Item type | Current library | Home library | Call number | Copy number | Status | Barcode | |
---|---|---|---|---|---|---|---|
![]() |
قاعة الرسائل الجامعية - الدور الاول | المكتبة المركزبة الجديدة - جامعة القاهرة | Cai01.11.03.Ph.D.2016.Ah.A (Browse shelf(Opens below)) | Not for loan | 01010110071038000 | ||
![]() |
مخـــزن الرســائل الجـــامعية - البدروم | المكتبة المركزبة الجديدة - جامعة القاهرة | Cai01.11.03.Ph.D.2016.Ah.A (Browse shelf(Opens below)) | 71038.CD | Not for loan | 01020110071038000 |
Browsing المكتبة المركزبة الجديدة - جامعة القاهرة shelves Close shelf browser (Hides shelf browser)
Thesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Medical Biochemistry
Hepatitis C virus (HCV) is remarkable at disrupting human immunity to establish chronic infection. Chronic HCV is associated with T cell imbalance, Also IFN-Ü and/or ribavirin used in the treatment of chronic HCV cause teffs / tregs imbalance and this imbalance is associated with autoantibodies production with or without autoimmune hepatitis. The main objectives of the present study to investigate how Tregs are regulated in patients chronically infected with HCV (by measuring Tregs markers granzyme 2, CD69 and FoxP3) and to investigate the effect of IFN-a and/or ribavirin on Teffs/Tregs balance and to study the association of Teffs / Tregs balance with the presence of antinuclear antibody (by measuring Teffs markers TNFRSF4, CD4, CD25 and INFG). The study was conducted on 120 patients classified into 4 groups; Group I. (30 persons): included healthy subjects served as a control group, Group II. (30 patients): included treatment naïve HCV chronically infected patients, Group III. (30 patients): included HCV chronically infected patients treated with IFN- Ü and/or ribavirin (the standard of care therapy), Group VI. (30 patients): included HCV chronically infected patients with associated non organ specific autoantibody
Issued also as CD
There are no comments on this title.